Latest Safety News

Visionflex Group has landed a significant contract with BHP to deploy its telehealth technology across 13 remote medical centres and a HEMS aircraft in Western Australia, aiming to revolutionize healthcare delivery for mining workers.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Vection Technologies has partnered with Laerdal Italia to integrate XR and AI solutions into healthcare simulation, aiming to generate $1.7 million in revenue over three years and expand across Europe.

New Hope Corporation reports steady coal production but a 27% drop in EBITDA amid falling prices and rail constraints, prompting revised FY25 guidance.

Mantle Minerals has secured a $65,000 co-funded drilling grant from the WA Government to advance its Mt Berghaus gold exploration in the Mallina Basin.

Great Divide Mining is poised to restart operations at its Challenger Gold Mine in Adelong, NSW, marking a pivotal shift from exploration to production with first gold expected imminently.

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.

Catalyst Metals has received the final environmental approval to begin mining at its Trident Gold Project, marking a key step in its plan to double production at the Plutonic Gold Belt.

Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.